secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0000950170-24-067644
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA darovasertib Phase 2 uveal melanoma data: 75% eye saved, 47% median tumor shrinkage
--------------------------------------------------------------------------------

- Investigator-sponsored Phase 2: 75% of enucleation patients (9/12) had eye saved (converted to brachytherapy/EBRT) after 6 months.
- Median tumor shrinkage 47% (max volume change) in 12 enucleation patients; 67% had >30% shrinkage after 6 months.
- Company-sponsored Phase 2: 8 patients at ≥4 months showed median tumor volume shrinkage 72%; majority of enucleation patients converted to eye saved.
- Drug-related AEs predominantly Grade 1-2; no drug-related serious AEs in either trial.
- Data presented at ASCO 2024; trial enrolled over 40 patients across 14+ sites globally.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000095017024067644/0000950170-24-067644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000095017024067644/idya-20240603.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-067644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer